Effect of donpezil and liothyronine on cagnitive symptom in patient with mood disorder in the depression phas under electroconvolsive therapy

Effect of donepezil and liothyronine on cognitive symptom in patient with mood disorder in the depression phase under electroconvulsive therapy (clinical trail-double blind)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220515054864N1

Enrollment

Registered

2022-08-02

Start date

2022-06-06

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of donepezil and liothyronine on cognitive symptom in patient with mood disorder in the depression phase under electroconvulsive therapy. Major depressive disorder, single episode

Interventions

Intervention 1: First intervention group: Donepezil will be started 24 hours before electroshock therapy with a daily dose of 5 mg and this daily dose will continue for 8 weeks in this group. Interven

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: In this clinical trial, 60 patients over the age of 20 and under 50 with the mood phase of mood disorders between 1400 and 1402 are candidates for ECT.

Exclusion criteria

Exclusion criteria: Patients with a history of alcohol and other substance use within one month prior to enrollment, epilepsy, mental retardation, illiteracy, cognitive impairment such as delirium and dementia, and mental retardation with a history of Donepezil use within one month prior to enrollment. Anemia, malnutrition, and substance use disorders will be excluded from the study based on the DSM5 criteria patients who discontinue treatment.

Design outcomes

Primary

Measure	Time frame
The overall score of Eden Brook test after ECT in 5 and 10 mg donepezil groups and liothyronine group. Timepoint: Patients' cognitive ability will be assessed 24 hours before and 24 hours after the end of ECT sessions, as well as one month and two months after the end of ECT using the Eden Brook cognitive examination test. Method of measurement: Aden Brook Cognitive Test Revised Version (ACE-R): Aden Brook Cognitive Test for diagnosing dementia in the early stages of the disease was made by Matura Nat and colleagues, which is capable of distinguishing between types of dementia such as Alzheimer's disease, front-temporal dementia, paralysis It is progressive in the superior nucleus and other parkinsonian syndromes and helps in the diagnosis of cognitive disorders.	—

Measure

Time frame

The overall score of Eden Brook test after ECT in 5 and 10 mg donepezil groups and liothyronine group. Timepoint: Patients' cognitive ability will be assessed 24 hours before and 24 hours after the end of ECT sessions, as well as one month and two months after the end of ECT using the Eden Brook cognitive examination test. Method of measurement: Aden Brook Cognitive Test Revised Version (ACE-R): Aden Brook Cognitive Test for diagnosing dementia in the early stages of the disease was made by Matura Nat and colleagues, which is capable of distinguishing between types of dementia such as Alzheimer's disease, front-temporal dementia, paralysis It is progressive in the superior nucleus and other parkinsonian syndromes and helps in the diagnosis of cognitive disorders.

—

Secondary

Measure	Time frame
It does not have a secondary variable. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAngela Hamidia

Babol University of Medical Sciences

angela_7633@yahoo.com+98 11 4254 9827

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026